MX2022010378A - Formulacion de daptomicina. - Google Patents
Formulacion de daptomicina.Info
- Publication number
- MX2022010378A MX2022010378A MX2022010378A MX2022010378A MX2022010378A MX 2022010378 A MX2022010378 A MX 2022010378A MX 2022010378 A MX2022010378 A MX 2022010378A MX 2022010378 A MX2022010378 A MX 2022010378A MX 2022010378 A MX2022010378 A MX 2022010378A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- solid
- daptomycin
- present description
- daptomicin
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 108010013198 Daptomycin Proteins 0.000 abstract 3
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 abstract 3
- 229960005484 daptomycin Drugs 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- -1 aliphatic amino acid Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982945P | 2020-02-28 | 2020-02-28 | |
| PCT/EP2021/054841 WO2021170807A1 (en) | 2020-02-28 | 2021-02-26 | Daptomycin formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010378A true MX2022010378A (es) | 2022-09-21 |
Family
ID=74797935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010378A MX2022010378A (es) | 2020-02-28 | 2021-02-26 | Formulacion de daptomicina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230068866A1 (enExample) |
| EP (1) | EP4110303A1 (enExample) |
| JP (2) | JP2023516957A (enExample) |
| CN (2) | CN118873500A (enExample) |
| AU (1) | AU2021227095B2 (enExample) |
| BR (1) | BR112022015571A2 (enExample) |
| CA (1) | CA3168727A1 (enExample) |
| MX (1) | MX2022010378A (enExample) |
| WO (1) | WO2021170807A1 (enExample) |
| ZA (1) | ZA202208343B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2770366C2 (ru) | 2017-08-31 | 2022-04-15 | Кселлия Фармасьютикалз Апс | Препараты даптомицина |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003055256A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第ｘｉｉｉ因子製剤 |
| RU2607526C2 (ru) | 2009-11-23 | 2017-01-10 | Кьюбист Фармасьютикалз ЭлЭлСи | Липопептидные композиции и родственные способы |
| RU2770366C2 (ru) * | 2017-08-31 | 2022-04-15 | Кселлия Фармасьютикалз Апс | Препараты даптомицина |
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
-
2021
- 2021-02-26 EP EP21708627.1A patent/EP4110303A1/en active Pending
- 2021-02-26 BR BR112022015571A patent/BR112022015571A2/pt unknown
- 2021-02-26 AU AU2021227095A patent/AU2021227095B2/en active Active
- 2021-02-26 US US17/794,734 patent/US20230068866A1/en active Pending
- 2021-02-26 CA CA3168727A patent/CA3168727A1/en active Pending
- 2021-02-26 CN CN202410944805.5A patent/CN118873500A/zh active Pending
- 2021-02-26 CN CN202180011662.7A patent/CN115038431B/zh active Active
- 2021-02-26 JP JP2022551653A patent/JP2023516957A/ja active Pending
- 2021-02-26 WO PCT/EP2021/054841 patent/WO2021170807A1/en not_active Ceased
- 2021-02-26 MX MX2022010378A patent/MX2022010378A/es unknown
-
2022
- 2022-07-26 ZA ZA2022/08343A patent/ZA202208343B/en unknown
-
2025
- 2025-07-18 JP JP2025120933A patent/JP2025142200A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118873500A (zh) | 2024-11-01 |
| US20230068866A1 (en) | 2023-03-02 |
| ZA202208343B (en) | 2024-11-27 |
| CA3168727A1 (en) | 2021-09-02 |
| BR112022015571A2 (pt) | 2022-09-27 |
| AU2021227095B2 (en) | 2024-02-22 |
| AU2021227095A1 (en) | 2022-08-25 |
| JP2025142200A (ja) | 2025-09-30 |
| JP2023516957A (ja) | 2023-04-21 |
| CN115038431B (zh) | 2024-08-09 |
| CN115038431A (zh) | 2022-09-09 |
| WO2021170807A1 (en) | 2021-09-02 |
| EP4110303A1 (en) | 2023-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021023457A2 (pt) | Composto, uso do composto, composição, e, métodos para preparar a composição e um composto | |
| CO2023014807A2 (es) | Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras | |
| AR070498A1 (es) | Composicion detergente que comprende lipasa | |
| CO5690620A2 (es) | Preparacion farmaceutica que comprende un anticuerpo contra el receptor egf | |
| PE20121405A1 (es) | Excipiente solubilizante para vacunas de virus completo inactivado | |
| MX2022007275A (es) | Composiciones de acidos biliares y compuestos de fenilbutirato. | |
| BR112013017884A2 (pt) | varredura de microcolônia encapsulada com gel | |
| MX2022010378A (es) | Formulacion de daptomicina. | |
| MX2023002117A (es) | Forma amorfa de un inhibidor de malt1 y formulaciones de este. | |
| MY156772A (en) | Composition and method for controlling plant diseases description | |
| AR123165A1 (es) | Un método para la producción de composiciones protéicas | |
| BR112014002624A8 (pt) | Microorganismo recombinante e cultura de microorganismo recombinante | |
| CO2021013926A2 (es) | Glicoproteínas sialiladas | |
| BR112022019411A2 (pt) | Composições de vacina estabilizadas | |
| CL2024003023A1 (es) | Inhibidores lrrk2. | |
| MY197497A (en) | Anti-pd-l1 antibody for detecting pd-l1 | |
| CL2024002284A1 (es) | Procesos para la preparación de alfa-hidroxi ésteres por esterificación de alfa-hidroxiácidos | |
| CL2022002854A1 (es) | Formulación estable | |
| PH12020551154A1 (en) | Method for suppressing discoloration of external composition containing adenosine phosphate and tranexamic acid | |
| BR112018070033A2 (pt) | preparação enzimática, método para produzir um produto de pancreatina, composição farmacêutica e método para tratar insuficiência pancreática exócrina | |
| MX2023014616A (es) | Formulaciones de anticuerpos anti-pd1. | |
| MX2023008406A (es) | Formulacion farmaceutica. | |
| MX2024007018A (es) | Sintesis de glufosinato mediante el uso de un proceso basado en hidantoinasa. | |
| MX2024011837A (es) | Procedimiento de preparacion de esteres cis-4-aminotetrahidrofuranos-2-carboxilicos | |
| UY40132A (es) | Supresión de la respuesta de evitación de la sombra en las plantas |